A 2026 BMJ study found GLP-1 drugs like Ozempic carry a 37–68% higher alopecia risk vs. other diabetes medications. The post ...

Results shows disease control in more than 80 percent of patients and cancer shrinkage in nearly 20 percent, offering ...

Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and ...

Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and the number of new cases is predicted ...

Each additional hour spent napping during the day tracks with a roughly 13 percent higher risk of dying from any cause, according to research synthesized by lead author Chenlu Gao and reported by ...

Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be ...

Making carbohydrate-derived drugs from naturally occurring sugars often requires chemists to temporarily shield the sugar’s ...

The field of pediatric clinical pharmacology faces persistent challenges in balancing therapeutic innovation with safety, particularly when treating ...

Because of its heterogenous presentation, Sjögren disease is commonly misdiagnosed, leading to delays in treatment ...

If you like knowing about the finest antagonistic figures in gaming, I invite you to read this list of the ten best video ...

Complement inhibitors to treat geographic atrophy (GA) were associated with thickening of the retinal nerve fiber layer (RNFL ...

Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell ...